Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: Granulocyte Colony Stimulating Factor (GCSF); Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Phase Contrast Mammography; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Neoplasm
Interventions: Vinorelbine, Capecitabine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: ARV-471, Abemaciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more

Conditions: Infected Seroma After Surgical Procedure
Interventions: Penrose drain placement; Device
Lead sponsor: Michigan State University; Other
Eligibility: 45 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
Interventions: INCB047986, Gemcitabine, nab-paclitaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas

Conditions: Cancer-related Fatigue, Breast Cancer, Prostate Cancer
Interventions: Telehealth Exercise Program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Missoula, Montana

Conditions: Breast Cancer
Interventions: Ixabepilone, Cyclophosphamide; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 20
States / cities: Aventura, Florida • Fort Myers, Florida • Lakeland, Florida + 16 more

Conditions: Pseudoxanthoma Elasticum
Interventions: Non Interventional; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypersensitivity Reactions
Interventions: Not listed
Lead sponsor: Lumicell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Mobile, Alabama • Palo Alto, California

Conditions: Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more

Conditions: Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
Interventions: Azacitidine (Vidaza), Nab-paclitaxel (Abraxane); Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acne Vulgaris
Interventions: Sebacia Microparticles, Nd:Yag Laser; Device
Lead sponsor: Sebacia, Inc.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Miami, Florida + 8 more

Conditions: Breast Cancer
Interventions: Photon, Proton; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 21 Years and older
Enrollment: 1,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more

Conditions: Melanoma
Interventions: Temozolomide, Bevacizumab; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Santa Monica, California • Miami Beach, Florida

Conditions: Breast Cancer
Interventions: Paclitaxel, Cyclophosphamide, Carboplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 70 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Milford, Massachusetts + 2 more

Conditions: Diffuse Systemic Sclerosis
Interventions: Fresolimumab; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Disorders, Eczema, Atopic
Interventions: Dupilumab, Auto-injector Device, Prefilled syringe; Drug · Device
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more

Conditions: Healthy Volunteers, Psoriasis
Interventions: PBI-100 Topical Cream, Vehicle Cream; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions: Chatbot, Video Education; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Letrozole, Anastrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 33 Years to 96 Years · Female only
Enrollment: 4,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 42
States / cities: Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more

Conditions: Acne Vulgaris
Interventions: Tretinoin Cream 0.025%; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,030 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Nail Diseases
Interventions: Suzetrigine, Oxycodone/Acetaminophen, Acetaminophen, Ibuprofen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, Fatigue
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Visibility of Lesion Characteristics With Phase Contrast Mammography

Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Post-market Safety Study of LUMISIGHT

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

'ADVANCE' (A Pilot Trial)

Fresolimumab In Systemic Sclerosis

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

OPTimizing Treatment Focused Genetic Testing IN Cancer

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

Post-op Analgesia of Nail Unit Procedures

Role of Beta-Endorphin in Cancer Therapy Fatigue